Literature DB >> 16909384

The value of molecular haplotypes in a family-based linkage study.

E M Gillanders1, J V Pearson, A J M Sorant, J M Trent, J R O'Connell, J E Bailey-Wilson.   

Abstract

Novel methods that could improve the power of conventional methods of gene discovery for complex diseases should be investigated. In a simulation study, we aimed to investigate the value of molecular haplotypes in the context of a family-based linkage study. The term "haplotype" (or "haploid genotype") refers to syntenic alleles inherited on a single chromosome, and we use the term "molecular haplotype" to refer to haplotypes that have been determined directly by use of a molecular technique such as long-range allele-specific polymerase chain reaction. In our study, we simulated genotype and phenotype data and then compared the powers of analyzing these data under the assumptions that various levels of information from molecular haplotypes were available. (This information was available because of the simulation procedure.) Several conclusions can be drawn. First, as expected, when genetic homogeneity is expected or when marker data are complete, it is not efficient to generate molecular haplotyping information. However, with levels of heterogeneity and missing data patterns typical of complex diseases, we observed a 23%-77% relative increase in the power to detect linkage in the presence of heterogeneity with heterogeneity LOD scores >3.0 when all individuals are molecularly haplotyped (compared with the power when only standard genotypes are used). Furthermore, our simulations indicate that most of the increase in power can be achieved by molecularly haplotyping a single individual in each family, thereby making molecular haplotyping a valuable strategy for increasing the power of gene mapping studies of complex diseases. Maximization of power, given an existing family set, can be particularly important for late-onset, often-fatal diseases such as cancer, for which informative families are difficult to collect.

Entities:  

Mesh:

Year:  2006        PMID: 16909384      PMCID: PMC1559540          DOI: 10.1086/506626

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  27 in total

1.  Experimentally-derived haplotypes substantially increase the efficiency of linkage disequilibrium studies.

Authors:  J A Douglas; M Boehnke; E Gillanders; J M Trent; S B Gruber
Journal:  Nat Genet       Date:  2001-08       Impact factor: 38.330

2.  Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease.

Authors:  J D Rioux; M J Daly; M S Silverberg; K Lindblad; H Steinhart; Z Cohen; T Delmonte; K Kocher; K Miller; S Guschwan; E J Kulbokas; S O'Leary; E Winchester; K Dewar; T Green; V Stone; C Chow; A Cohen; D Langelier; G Lapointe; D Gaudet; J Faith; N Branco; S B Bull; R S McLeod; A M Griffiths; A Bitton; G R Greenberg; E S Lander; K A Siminovitch; T J Hudson
Journal:  Nat Genet       Date:  2001-10       Impact factor: 38.330

3.  Caution on pedigree haplotype inference with software that assumes linkage equilibrium.

Authors:  Daniel J Schaid; Shannon K McDonnell; Liang Wang; Julie M Cunningham; Stephen N Thibodeau
Journal:  Am J Hum Genet       Date:  2002-10       Impact factor: 11.025

4.  Haplotype inference in random population samples.

Authors:  Shin Lin; David J Cutler; Michael E Zwick; Aravinda Chakravarti
Journal:  Am J Hum Genet       Date:  2002-10-17       Impact factor: 11.025

5.  The impact of genotyping error on haplotype reconstruction and frequency estimation.

Authors:  Katherine M Kirk; Lon R Cardon
Journal:  Eur J Hum Genet       Date:  2002-10       Impact factor: 4.246

6.  Relative efficiency of ambiguous vs. directly measured haplotype frequencies.

Authors:  Daniel J Schaid
Journal:  Genet Epidemiol       Date:  2002-11       Impact factor: 2.135

7.  Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness.

Authors:  C M Drysdale; D W McGraw; C B Stack; J C Stephens; R S Judson; K Nandabalan; K Arnold; G Ruano; S B Liggett
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

8.  A method for developing high-density SNP maps and its application at the type 1 angiotensin II receptor (AGTR1) locus.

Authors:  Anthony Antonellis; John J Rogus; Luis H Canani; Yuchiro Makita; Marcus G Pezzolesi; MoonSuk Nam; Daniel Ng; Dariusz Moczulski; James H Warram; Andrzej S Krolewski
Journal:  Genomics       Date:  2002-03       Impact factor: 5.736

9.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease.

Authors:  J P Hugot; M Chamaillard; H Zouali; S Lesage; J P Cézard; J Belaiche; S Almer; C Tysk; C A O'Morain; M Gassull; V Binder; Y Finkel; A Cortot; R Modigliani; P Laurent-Puig; C Gower-Rousseau; J Macry; J F Colombel; M Sahbatou; G Thomas
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

10.  Investigation of altering single-nucleotide polymorphism density on the power to detect trait loci and frequency of false positive in nonparametric linkage analyses of qualitative traits.

Authors:  Alison P Klein; Ya-Yu Tsai; Priya Duggal; Elizabeth M Gillanders; Michael Barnhart; Rasika A Mathias; Ian P Dusenberry; Amy Turiff; Peter S Chines; Janet Goldstein; Robert Wojciechowski; Wayne Hening; Elizabeth W Pugh; Joan E Bailey-Wilson
Journal:  BMC Genet       Date:  2005-12-30       Impact factor: 2.797

View more
  2 in total

1.  Homozygosity haplotype allows a genomewide search for the autosomal segments shared among patients.

Authors:  Hitoshi Miyazawa; Masaaki Kato; Takuya Awata; Masakazu Kohda; Hiroyasu Iwasa; Nobuyuki Koyama; Tomoaki Tanaka; Shunei Kyo; Yasushi Okazaki; Koichi Hagiwara
Journal:  Am J Hum Genet       Date:  2007-05-02       Impact factor: 11.025

2.  An efficient method for multi-locus molecular haplotyping.

Authors:  Bernard A Konfortov; Alan T Bankier; Paul H Dear
Journal:  Nucleic Acids Res       Date:  2006-12-07       Impact factor: 16.971

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.